Lighting the way to tumor destruction

Area of Science:

• Oncology
• Nanotechnology
• Biochemistry

Background:

• Targeted protein degradation is a promising cancer therapeutic strategy.
• Achieving tumor-specific delivery of proteolysis-targeting chimeras (PROTACs) remains a significant challenge.
• Current PROTAC delivery methods can lead to off-target effects.

Purpose of the Study:

• To develop a novel photoactivatable approach for targeted PROTAC delivery and protein degradation.
• To overcome the challenge of achieving tumor-specific protein loss using PROTACs.
• To evaluate the efficacy of nanoformulated PROTACs (NAPs) in a preclinical cancer model.

Main Methods:

• Development of nanoformulated PROTACs (NAPs) with photoactivatable properties.
• Utilizing near-infrared (NIR) light to trigger PROTAC release.
• In vivo studies in mouse tumor models to assess protein degradation efficacy.

Main Results:

• Demonstrated precise release of PROTACs from nanoparticles upon NIR light activation.
• Achieved significant tumor-specific protein degradation in mouse models.
• NAPs showed potential for targeted cancer therapy with reduced off-target effects.

Conclusions:

• Photoactivatable nanoformulated PROTACs (NAPs) represent a novel and effective strategy for targeted cancer therapy.
• NIR-light-triggered PROTAC delivery enables precise protein degradation within tumors.
• This approach holds promise for improving the safety and efficacy of PROTAC-based cancer treatments.